Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. (Q37981001)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Rosa Maria Hernandez

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Susana Patricia Egusquiaguirre

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

José Luis Pedraz

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Translational Oncology

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

83-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12094-012-0766-6

22 January 2020

exact match

0 references

cites work

Principles of cancer therapy: oncogene and non-oncogene addiction

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Cooperative nanomaterial system to sensitize, target, and treat tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

The present and future of nanotechnology in human health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Nanotech approaches to drug delivery and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Nanomedicine: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Nanoparticle therapeutics: an emerging treatment modality for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Drug delivery systems: entering the mainstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Nanomaterials for cancer therapy and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Biodegradable nanoparticles for drug and gene delivery to cells and tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Delivering nanomedicine to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Therapeutic nanoparticles for drug delivery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Glycolysis inhibition for anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Targeted drug delivery to tumors: myths, reality and possibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Active targeting schemes for nanoparticle systems in cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Factors affecting the clearance and biodistribution of polymeric nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

The effect of particle design on cellular internalization pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Ligand-targeted liposomal anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Liposomal encapsulated anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Advances of cancer therapy by nanotechnology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

21 January 2018

The taxanes: an update

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Nanomedicine based approaches for the delivery of siRNA in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Knocking down barriers: advances in siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Emerging nanopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Lipid nanomedicines for anticancer drug therapy

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

21 January 2018

12 December 2020

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Methotrexate-loaded SLNs prepared by coacervation technique: in vitro cytotoxicity and in vivo pharmacokinetics and biodistribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0766-6

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

21 January 2018

1 reference

12 December 2020

Lymphatic metastasis in the absence of functional intratumor lymphatics

1 reference

12 December 2020

Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer

1 reference

12 December 2020

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

1 reference

12 December 2020

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors

1 reference

12 December 2020

Doxorubicin-induced cardiomyopathy

1 reference

12 December 2020

Clinical toxicities encountered with paclitaxel (Taxol).

1 reference

12 December 2020

Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin

1 reference

12 December 2020

Lipoplatin formulation review article

1 reference

12 December 2020

Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.

1 reference

12 December 2020

Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging

1 reference

12 December 2020

Nanomedicine transforms drug delivery

1 reference

12 December 2020

Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems

1 reference

12 December 2020

Passive and active drug targeting: drug delivery to tumors as an example

1 reference

12 December 2020

10.1007/S12094-012-0766-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22301396%20AND%20SRC:MED&resulttype=core&format=json

release_g7u3aedjdvh77esmatytnatuki

22 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g7u3aedjdvh77esmatytnatuki

24 November 2022

mapped directly with Wikidata item

1 reference